Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life
Abstract Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are few, the KCNJ6 gene is a promising target for investig...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-21180-w |
| _version_ | 1811336410640154624 |
|---|---|
| author | Deniz Ozberk Alison Haywood Heidi G. Sutherland Chieh Yu Cassie L. Albury Mathew Zunk Rani George Phillip Good Lyn R. Griffiths Janet Hardy Larisa M. Haupt |
| author_facet | Deniz Ozberk Alison Haywood Heidi G. Sutherland Chieh Yu Cassie L. Albury Mathew Zunk Rani George Phillip Good Lyn R. Griffiths Janet Hardy Larisa M. Haupt |
| author_sort | Deniz Ozberk |
| collection | DOAJ |
| description | Abstract Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are few, the KCNJ6 gene is a promising target for investigating genetic factors that contribute to pain and analgesia response. This is the first association study on polymorphisms in KCNJ6 and response to methadone for pain management in advanced cancer. Fifty-four adult patients with advanced cancer were recruited across two study sites in a prospective, open label, dose individualisation study. Significant associations have been previously shown for rs2070995 and opioid response in opioid substitution therapy for heroin addiction and studies in chronic pain, with mixed results seen in postoperative pain. In this study, no associations were shown for rs2070995 and methadone dose or pain score, consistent with other studies conducted in patients receiving opioids for pain in advanced cancer. There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians. |
| first_indexed | 2024-04-13T17:39:04Z |
| format | Article |
| id | doaj.art-bf9bdce28ad74f1da1d63fcf9f426c15 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-13T17:39:04Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-bf9bdce28ad74f1da1d63fcf9f426c152022-12-22T02:37:14ZengNature PortfolioScientific Reports2045-23222022-10-011211710.1038/s41598-022-21180-wAssociation of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-lifeDeniz Ozberk0Alison Haywood1Heidi G. Sutherland2Chieh Yu3Cassie L. Albury4Mathew Zunk5Rani George6Phillip Good7Lyn R. Griffiths8Janet Hardy9Larisa M. Haupt10School of Pharmacy and Medical Sciences, Griffith UniversitySchool of Pharmacy and Medical Sciences, Griffith UniversityStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of TechnologyStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of TechnologyStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of TechnologySchool of Pharmacy and Medical Sciences, Griffith UniversitySchool of Pharmacy and Medical Sciences, Griffith UniversityMater Research Institute, The University of QueenslandStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of TechnologyMater Research Institute, The University of QueenslandStem Cell and Neurogenesis Group, Genomics Research Centre, Centre for Genomics and Personalised Health, Queensland University of TechnologyAbstract Opioids are the therapeutic agents of choice to manage moderate to severe pain in patients with advanced cancer, however the unpredictable inter-individual response to opioid therapy remains a challenge for clinicians. While studies are few, the KCNJ6 gene is a promising target for investigating genetic factors that contribute to pain and analgesia response. This is the first association study on polymorphisms in KCNJ6 and response to methadone for pain management in advanced cancer. Fifty-four adult patients with advanced cancer were recruited across two study sites in a prospective, open label, dose individualisation study. Significant associations have been previously shown for rs2070995 and opioid response in opioid substitution therapy for heroin addiction and studies in chronic pain, with mixed results seen in postoperative pain. In this study, no associations were shown for rs2070995 and methadone dose or pain score, consistent with other studies conducted in patients receiving opioids for pain in advanced cancer. There are many challenges in conducting studies in advanced cancer with significant attrition and small sample sizes, however it is hoped that the results of our study will contribute to the evidence base and allow for continued development of gene-drug dosing guidelines for clinicians.https://doi.org/10.1038/s41598-022-21180-w |
| spellingShingle | Deniz Ozberk Alison Haywood Heidi G. Sutherland Chieh Yu Cassie L. Albury Mathew Zunk Rani George Phillip Good Lyn R. Griffiths Janet Hardy Larisa M. Haupt Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life Scientific Reports |
| title | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life |
| title_full | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life |
| title_fullStr | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life |
| title_full_unstemmed | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life |
| title_short | Association of KCNJ6 rs2070995 and methadone response for pain management in advanced cancer at end-of-life |
| title_sort | association of kcnj6 rs2070995 and methadone response for pain management in advanced cancer at end of life |
| url | https://doi.org/10.1038/s41598-022-21180-w |
| work_keys_str_mv | AT denizozberk associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT alisonhaywood associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT heidigsutherland associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT chiehyu associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT cassielalbury associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT mathewzunk associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT ranigeorge associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT phillipgood associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT lynrgriffiths associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT janethardy associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife AT larisamhaupt associationofkcnj6rs2070995andmethadoneresponseforpainmanagementinadvancedcanceratendoflife |